Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 132Carcinoma, Transitional Cell 91Carcinoma, Non-Small-Cell Lung 84Urinary Bladder Neoplasms 81Melanoma 75Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 49Colorectal Neoplasms 41Ovarian Neoplasms 36Stomach Neoplasms 35Triple Negative Breast Neoplasms 33Neoplasm Metastasis 32Uterine Cervical Neoplasms 31Neoplasms 28Kidney Neoplasms 27Breast Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Lung Neoplasms 26Pancreatic Neoplasms 23Carcinoma, Hepatocellular 23Esophageal Neoplasms 21Head and Neck Neoplasms 20Endometrial Neoplasms 18Small Cell Lung Carcinoma 16Carcinoma, Merkel Cell 11Mesothelioma 9Cholangiocarcinoma 9Ureteral Neoplasms 8Sarcoma 8Carcinoma, Ovarian Epithelial 8

Interventions

padeliporfin 5Abiraterone Acetate 3Pluvicto 2Paclitaxel 2sipuleucel-T 1rucaparib 1pembrolizumab 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gallium 68 PSMA-11 1apalutamide 1abiraterone 1Therapeutics 1Suspensions 1Radiotherapy 1Radiation Dose Hypofractionation 1Powders 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 1EPI-506 1Chemical Fractionation 1Biopsy, Needle 1BAY 86-7548 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × pembrolizumab × Genitourinary × Clear all
NCT02499952 2022-07-11

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Terminated
12 enrolled 14 charts
GenitourinaryGynecologic

Nonseminomatous germ cell tumor, Genital Neoplasms, Female, Genital Neoplasms, Male, Mediastinal Neoplasms, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡